Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

IDIBELL Licenses to Janus a Patent for the Treatment of Immune Diseases

Published: Thursday, December 06, 2012
Last Updated: Thursday, December 06, 2012
Bookmark and Share
The technology has been developed entirely in the Institute.

The Bellvitge Biomedical Research Institute (IDIBELL) has signed a licensing agreement with the company Janus Developments of a patent for an immunomodulatory product for treating immune diseases such as autoimmune diseases, sepsis, hypersensitivity disorders (including, allergic reactions) or post-transplant rejection. The patent has been developed by the researcher of the Human Molecular Genetics group Josep Maria Aran and his team.

The invention relates to a concrete form of C4BP protein (C4b-binding protein), which is able to inhibit other proteins in the complement system, a major component of the innate immune response.

Step into the market

Many years will be needed before the product developed by Dr. Aran can be applied in humans. It will require additional preclinical studies and clinical trials in humans. In this sense, the signing of the license agreement is an important step to complete these studies and to become in the future a pharmaceutical product.

The head of the Technology Transfer Office (TTO) at IDIBELL, Montse Ballarín, highlights the fact that "the license products developed at our institution reflects the IDIBELL strategy as a public research centre, to bring our ideas and inventions to market."

Ballarín stresses that the transfer of a technology or a product to industry is not an easy process. "You have to offer a good product that meets a market need, to solve an unsolved problem, a technically and economically feasible production, a will to buy by the health system and a long list of conditions that are overcome before to achieve the interest of the company." Finally, "there is a good bargain to adequately protect the interests of inventors and the institution", explains the OTRI responsible.

Janus Developments is a company dedicated to biomedical knowledge transfer to the market. Currently develop eleven projects based on patents originated at several universities and research centres. In addition, Janus timely collaborates in defining and implementing various companies and foundations. Janus Developments supports IDIBELL in transfer activities, from identifying technologies to the introduction to market.

The license signed with Janus is the first patent that IDIBELL, through its TTO, has been transferred to a company outside the campus (previously had managed licensing contracts with spin-offs arising from the institution). Also recently it has been transferred a diagnostic technology and a patent to a multinational pharmaceutical company. At this time, IDIBELL is on track to close two licensing agreements over two patents developed by researchers at the centre.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Patented, a Molecule that Opens the Door to Develop New Drugs Against Immune Rejection
Researchers have patented a peptide that inhibits the immune response activated by the enzyme calcineurin which could serve to develop new more specific immunosuppressive drugs.
Thursday, August 01, 2013
Genetically Modified Stem Cells are Effective Against Acute Respiratory Diseases
Administration of genetically modified mesenchymal stem cells regenerates lung tissue and stops the inflammatory process in mice with acute lung injury.
Tuesday, June 18, 2013
Identified a Key Protein in Maintaining the Identity of B Lymphocytes
This finding could be useful for the study of blood diseases such as lymphoma and leukemia.
Monday, June 10, 2013
We Need Bacteria to Maintain a Good Immune System
Dr. Francisco Guarner, from the Vall d'Hebron University Hospital, talked about the functions of the bacteria in our body in the IDIBELL Seminar.
Thursday, October 25, 2012
Scientific News
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!